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Abstract
Experimental evolution has been used for various biotechnological applications including protein and microbial cell
engineering, but less commonly in the field of oncolytic virotherapy. Here, we sought to adapt a rapidly evolving RNA virus
to cells deficient for the tumor suppressor gene p53, a hallmark of cancer cells. To achieve this goal, we established four
independent evolution lines of the vesicular stomatitis virus (VSV) in p53-knockout mouse embryonic fibroblasts (p532/2
MEFs) under conditions favoring the action of natural selection. We found that some evolved viruses showed increased
fitness and cytotoxicity in p532/2 cells but not in isogenic p53+/+ cells, indicating gene-specific adaptation. However, full-
length sequencing revealed no obvious or previously described genetic changes associated with oncolytic activity. Half-
maximal effective dose (EC50) assays in mouse p53-positive colon cancer (CT26) and p53-deficient breast cancer (4T1) cells
indicated that the evolved viruses were more effective against 4T1 cells than the parental virus or a reference oncolytic VSV
(MD51), but showed no increased efficacy against CT26 cells. In vivo assays using 4T1 syngeneic tumor models showed that
one of the evolved lines significantly delayed tumor growth compared to mice treated with the parental virus or untreated
controls, and was able to induce transient tumor suppression. Our results show that RNA viruses can be specifically adapted
typical cancer features such as p53 inactivation, and illustrate the usefulness of experimental evolution for oncolytic
virotherapy.
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Introduction
Experimental evolution is routinely used to test evolutionary
hypotheses under controlled laboratory conditions [1,2] and in
several applied research fields in which natural selection is used to
direct specific traits towards pre-defined goals [3]. Directed
evolution has allowed researchers to produce proteins with novel
or enhanced functions [4], to modify microbial cells for
biotechnological applications [5], or even to improve software
and develop controllers for autonomous robots [6]. In the field of
virology, the classical procedures for creating live attenuated
vaccines include serial transfers in non-human hosts under
permissive conditions that tend to reduce viral fitness in humans,
as well as plaque-to-plaque transfers that allow for the accumu-
lation of deleterious mutations by random genetic drift [7].
Experimental evolution has also been used for predicting the
emergence of drug resistance in viruses [8].
Oncolytic virotherapy is an anti-cancer treatment strategy that
relies on the ability of viruses to induce selective killing of tumor
cells. Currently, there are approximately 100 ongoing or finished
phase I, II or III clinical trials involving a plethora of viruses,
including adenoviruses, herpes simplex virus, vaccinia virus,
parvoviruses, coxsackievirus, poliovirus, retroviruses, reoviruses,
measles virus, Newcastle disease virus, or vesicular stomatitis virus
(VSV) [9]. Clearly, the dominant approach in the field is to use
genetic engineering to make viruses more selective, potent, and
safer anti-cancer agents by deleting virulence genes, changing viral
envelope proteins to reset viral tropism, and using viruses as
vectors of ‘‘suicide’’ genes that are selectively expressed in cancer
cells, or of genes that increase susceptibility to radiation and
chemotherapy, among other strategies [9–12]. However, the
rational design of new oncolytic viruses is limited by our
incomplete understanding of the complex, extremely diverse,
and evolving nature of virus-host interactions. In addition, tumor
cells have widely varying properties depending on the cancer type
and patient, further complicating this approach [13].
One key aspect of viruses is that, as opposed to conventional
therapeutic agents, they are self-replicating and mutating entities
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and, therefore, are naturally amenable to evolutionary optimiza-
tion. Therefore, directed evolution should provide a useful
complementary approach to genetic engineering for creating
new oncolytic viruses or improving the performance of existing
ones. However, this approach has been seldom applied to
oncolytic virotherapy, albeit with a few notable exceptions [14–
19]. In one study, pools of adenoviruses from various serotypes
were passaged in human colon cancer cells, leading to the isolation
of a recombinant virus (ColoAd1) showing improved oncolytic
properties relative to the marketed strain [15]. The production of
new oncolytic adenoviruses has been enhanced by chemical
mutagenesis [19] or using low-fidelity polymerases to replicate the
viral genome [16], followed by serial passaging in target cancer
cells.
RNA viruses are also suitable for oncolytic virotherapy, and are
ideal systems for experimental evolution. Their high rates of
spontaneous mutation [20] and often elevated titers allow selection
to operate very efficiently, leading to the deterministic evolution of
fitness-related traits in the laboratory [21]. Also, their small and
compact genomes limit the number of alternative mutations that
can be selectively favored in a given environment [22] and, as a
result, the same substitutions often appear repeatedly in indepen-
dently evolving lines (parallel evolution) [23–26], facilitating the
analysis of the genetic basis of adaptation. Interestingly, selectively
advantageous substitutions in one environment tend to become
costly in alternate environments (antagonistic pleiotropy), thus
producing fitness tradeoffs that favor specialization in a particular
host [24,27–29]. These findings strongly suggest that experimental
evolution should provide a useful tool for obtaining RNA viruses
with increased selectively for tumor cells.
VSV is a prototypic, non-segmented, negative-stranded RNA
virus of the family Rhabdoviridae and shows some natural selectivity
for tumor cells [30]. We hypothesized that it should be possible to
increase VSV selectivity for tumor cells by adapting the virus to
cells in which the tumor suppressor gene p53 has been inactivated.
Since many cancers are p53-defective, viral adaptation to this
particular trait may have broad applicability. This approach also
allowed us to directly test for fitness tradeoffs associated with
adaptation to p532/2 cells by assaying the evolved viruses in
isogenic cells with normal p53 function. We found that, after 40
serial passages in p53-knockout mouse embryonic fibroblasts
(MEFs), VSV exhibited significantly increased fitness and
cytotoxicity in these cells, but that these changes tended to be
non-adaptive in normal MEFs, therefore indicating increased
selectivity for p53-deficient cells. However, full-length sequencing
did not reveal simple molecular signatures underlying this
phenotype. Finally, we also demonstrate p53-dependent oncolytic
activity in tumor cell cultures and in vivo using mouse 4T1 breast
and CT-26 colon cancer models.
Methods
Virus and cell culturing
Viral infectious particles were recovered from the VSV cDNA
clone originally created by Whelan et al. [31] by transfecting
BHK-21 cells as previously described [32]. This virus was used as
the founder of the evolution experiments, and was designated as
WT. Primary MEFs derived from wild type and p532/2
C57BL6 mice were isolated as previously described [33], cultured
in Dulbeco’s modified Eagle’s Medium (DMEM) (Invitrogen) with
10% fetal bovine serum (FBS) (Invitrogen), and passaged upon
confluence. p532/2 MEFs were discarded after passage 14 and
replaced with a fresh stock to avoid selection of additional
mutations. Primary, isogenic, p53+/+ MEFs used in viral fitness
and cell viability assays were also kept at a low passage number.
4T1 and CT-26 cells were obtained from the ATCC, cultured in
DMEM with 10% FBS and passaged upon confluence. All cells
were cultured at 37uC under 95% humidity, 5% CO2, and
atmospheric O2 levels. Viruses were titrated in BHK-21 cells for
convenience. In a pilot experiment, we determined that the plating
efficiencies of the WT in p532/2 and p53+/+ MEFs relative to
BHK-21 cells were 0.5360.04 and 0.6060.14, respectively. Viral
titers were subsequently corrected by taking plating efficiency into
account.
Experimental evolution
Monolayers containing 105 cells were inoculated with 56103
plaque forming units (pfu) of VSV (multiplicity of infection,
MOI = 0.05 pfu/cell) and incubated for 24 hours post inoculation
(hpi), the time required to reach a titer plateau of approximately
26107 pfu/mL, as determined in preliminary growth curves. The
supernatants were titrated after each passage and conveniently
diluted to infect fresh cells with a constant number of pfu during
the course of the experiment. Assuming a yield of approximately
1000 pfu/cell, the estimated number of viral generations (i.e.
infection cycles) per passage was ln(26107/5/103)/ln 103 = 1.2
[34].
Viral fitness
Monolayers containing 104 cells were inoculated with approx-
imately 103 pfu of the assayed virus (evolved or WT) and a
common competitor which was isogenic to the WT but carried the
single-nucleotide replacement A3853C in the plus-strand genome,
which confers resistance to a monoclonal antibody but is otherwise
selectively neutral [32]. The proportion of each competitor at
inoculation and at 24 hpi was determined by titrating the mix in
the presence and in the absence of antibody. Fitness relative to the
WT was calculated as (R24/R0)L/(R24/R0)WT, where R denotes
the titer ratio of the assayed virus to the common competitor at
inoculation (0) and 24 hpi (24) for the evolved (L) and WT viruses.
Four independent fitness assays were performed for each virus.
The plating efficiencies of the evolved lines in p532/2 and
p53+/+ MEFs relative to BHK-21 cells were not significantly
different from those of the WT (t-test: P.0.05).
Viral cytotoxicity
Cell suspensions containing 104 cells/well were inoculated at
MOI.1 pfu/cell, such that most cells became infected. Cell
viability was quantified at 18 hpi by adding 20 mL of a 20:1
(volume) MTS/PMS mix and measuring OD490 in a Multiskan
FC plate reader (Thermo Scientific). The MOI and incubation
time were chosen to provide an estimate of the toxic effect of the
virus after a single infection cycle independent of the growth rate
of the virus. The fraction of live cells was calculated as V = (ODi–
OD0)/(ODu–OD0), where sub-indexes i, u, and 0 refer to infected
wells, uninfected wells and the blank, respectively. Five indepen-
dent cytotoxicity measurements were taken for each virus.
Half-maximal effective dose (EC50)
Cell suspensions in 96-well plates (104 cells/well) were
inoculated at increasing MOI as indicated and cell viability was
quantified by adding Alamar Blue (20 mg/mL final concentration)
at 48 hpi, incubating for 2 h, and measuring fluorescence at
590 nm with a 530–560 nm excitation wavelength. The fraction
of live cells (V) was calculated as above, and the EC50 was
estimated by fitting the following model to the data using non-
linear least-squares regression: V~ 1{Vmin
1z(MOI=EC50
){h
, where Vmin is
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the minimal viability value, h measures the maximal rate of
viability loss, and MOI is the viral dose (pfu/cell).
Sequencing
Viral RNA was extracted from infected supernatants using the
NucleoSpin RNA Virus kit (Macherey-Nagel), reverse-transcribed
with AccuScript (Agilent Technologies), and used for PCR
amplification. The genome was amplified using four overlapping
PCR fragments (primer sequences available upon request), which
were column-purified and used for Sanger sequencing. Chro-
matograms were analyzed using the Staden software (http://
staden.sourceforge.net).
Western blotting
Confluent 60 mm dishes containing CT-26, 4T1 or Vero cells
were exposed to UV irradiation at 4 J/m2 for 0, 2, 5 and 10 s, and
16 h after irradiation cells were washed twice with ice-cold
Dulbecco’s PBS 16(PBS), harvested and lysed in a hypotonic
buffer (10 mM Tris-HCl pH 7.5, 1.5 mM MgCl2, 10 mM KCl,
2 mM DTT, 1 mM Pefabloc, 2 mM sodium vanadate, 4 mg/mL
pepstatin, 4 mg/mL leupeptin, and 4 mg/mL aprotinin) for 30 min
at 4uC, and centrifuged at 13,000 g for 10 min at 4uC to remove
debris. Equivalent amounts of protein were separated by SDS-
PAGE and wet-electrotransferred onto PDVF membranes
(Roche). Membranes were blocked for 1 h at room temperature
with blocking buffer (PBS, 0.1% Tween 20, and 5% nonfat dry
milk) and proteins were detected with antibodies against p21 (sc-
397, Santa Cruz), and p53 (sc-6243, Santa Cruz). Primary
antibodies were diluted 1:200 in dilution buffer (PBS, 0.1%
Tween 20, and 5% nonfat dry milk) and blots were incubated
overnight, followed by 1 h incubation with horseradish peroxidase
(HRP)-conjugated secondary anti-rabbit antibody (Santa Cruz)
(1:10,000). Peroxidase activity was revealed by enhanced chemi-
luminescence (Pierce). GAPDH was used as loading control.
Mouse infections
Virions were concentrated by ultracentrifugation, purified on 5–
50% Optiprep (Sigma) gradient and titrated prior to in vivo
assays. Six week-old female Balb/c mice were acclimatized for 2–4
days and inoculated subcutaneously in one flank with 36105 cells
resuspended in 100 mL PBS. When tumors reached an estimated
size of 220 mm3 (8 days for 4T1 and 11 days for CT-26), animals
were injected intratumorally with 50 mL of the purified virion
suspension containing 108 pfu. A second dose was administered to
4T1 tumors 7 days later. Mice were evaluated every 2–3 days for
signs of disease (weight loss, piloerection, anorexia, abnormal
behavior). Tumor size was estimated by taking two orthogonal
measures using an electronic caliper, and tumor volume was
calculated as = (length6width2)/2. Animals were euthanized if
tumor volumes exceeded 1700 mm3 or were highly ulcerated. To
test for differences in tumor growth among treatments (WT, L3
and mock-infected controls), we performed a one-way ANOVA in
which time was a covariate. These assays were carried out in strict
accordance with the ‘‘Guide to the Care and Use of Experimental
Animals’’, as published by the Canadian Council on Animal Care,
the provincial legislation entitled ‘‘The Animals for Research Act
of Province of Ontario’’ and approved by the Ethics Committee of
the University of Ottawa (protocol number ME-222).
Results
VSV recovered from an infectious cDNA clone (parental virus,
WT) was passaged 40 times in MEFs from p532/2 mice in four
replicate lines (L1–L4), which is the equivalent of approximately
50 generations (i.e. infection cycles) of viral evolution per line. For
line L3, we observed a significant increase in titer over time
(Spearman r= 0.421, P= 0.008), the titer at passage 40 being 3.4
times higher than at the start of the experiment (1.56108 versus
4.46107 pfu/mL). To more accurately test if the fitness of the
virus had increased in p532/2MEFs, we competed each evolved
line against a common, phenotypically marked, competitor
isogenic to the WT virus. This revealed that 3/4 lines (L2–L4)
showed significantly higher fitness than the WT (t-test: P,0.05),
with L3 showing the highest relative fitness (4.760.7; Figure 1a).
Since previous work with VSV and other viruses has shown that
fitness typically correlates with cytotoxicity [35,36], we expected
that that the evolved lines should also show increased ability to kill
p532/2MEFs. To test this, we measured changes in cell viability
after one infection cycle using the MTS assay for NADPH flux
associated with metabolic activity. This confirmed that the three
lines experiencing a fitness increase in p532/2 MEFs were also
more cytotoxic than the WT, and that L3 and L4 induced the
highest cell death levels (Figure 1b).
To ascertain whether the observed changes were specific to p53-
deficient cells, we performed fitness and cytotoxicity assays in
isogenic p53+/+ primary MEFs (Figure 1c, d). We found that lines
L1, L2, and L3 did not significantly increase their fitness in
p53+/+ cells (t-test: P.0.3). For L2 and L3, .90% of the fitness
gain was lost in p53+/+ cells, indicating that adaptation was
mostly gene-specific. In contrast, L4 also showed significantly
increased fitness in p53+/+ cells, indicating adaptation to MEFs or
to laboratory cell culturing conditions for this line. MTS assays in
p53+/+ MEFS revealed that L2, L3 and L4 showed similar
toxicity as the WT, whereas L1 was slightly less toxic (Figure 1d).
From these results, we conclude that lines L2 and L3 were
specifically adapted to p532/2 cells, L1 showed no significant
adaptation to p532/2 cells and a slight loss of virulence in
p53+/+ cells, and L4 showed significant but non p53-specific
adaptation.
Nearly full-length sequencing (.99% of the genome, bases 60 to
11,100) of the four evolved lines revealed that, in total, 13 different
substitutions were fixed and one more was polymorphic at passage
40, with 9/14 substitutions leading to amino acid replacements
(Figure 2). Most mutations occurred in genes P and G,
reproducing the higher natural variability of these genes [37,38].
Despite extensive parallel evolution has been reported in previous
experimental evolution studies with VSV [23–26], we found only
one repeated substitution (C10224U), which appeared as a
polymorphism in lines L2 and L4. Therefore, there were no clear
candidate mutations to confer specific adaptation to p532/2
MEFs, and we thus performed subsequent experiments with
viruses derived from passage 40 instead of engineering single-point
mutants.
We selected the L2 and L3 lines to characterize their oncolytic
activity in 4T1 breast and CT-26 colon cancer cells from Balb/c
mice, and we included the well-characterized oncolytic VSV
MD51 mutant as a reference [39,40]. We chose these two cell
types because 4T1 cells do not express a functional p53 protein,
whereas CT-26 cells showed apparently normal p53 function, as
revealed by Western blotting of p53 and the downstream p53-
activated protein p21 (Figure 3). Cells were infected with an
increasing MOI of each virus, assayed for viability at 48 hpi using
the Alamar blue oxidation-reduction test, and the EC50 was
estimated by non-linear least-squares regression (Figure 4). L2 and
L3 were more effective against 4T1 cells than the WT virus, as
indicated by their significant decrease in EC50. In contrast, the L3
and WT viruses were similarly active against p53-positive CT-26
cells, whereas L2 showed a two to threefold increase in EC50 in
Oncolytic Virus Evolution
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these cells. The VSV MD51 mutant was attenuated in both 4T1
and CT-26 cells as judged by the higher cell viability at increasing
MOI compared with L2, L3, or the WT.
Based on the results obtained in MEFs, 4T1 and CT-26 cells,
we chose L3 for further evaluation in syngeneic tumor grafts.
Twenty-five mice were engrafted with 4T1 cells and, after 8 days,
108 pfu of L3 or the WT were injected intratumorally in each of
10 mice (day 0) and re-injected after one week (day 7). A control
group of five mice was mock-inoculated with saline buffer (PBS).
Of the five animals treated with the L3 virus, two died at days 7
and 9 from non-tumor related causes. The experiment was
terminated on day 13, when 8/23 animals reached endpoint (4/5
untreated, 3/10 treated with the WT, and 1/8 treated with L3).
Over the entire course of the experiment, there were significant
differences in tumor growth among treatment groups (one-way
ANOVA, P,0.001), with L3 significantly delaying tumor
Figure 1. Evolution of viral fitness and cytotoxicity in MEFs. VSV was evolved in p532/2 MEFs for 40 serial passages (MOI = 0.05) and, for
each evolved lineage (L1–L4), fitness and cytotoxicity were assayed in p532/2 MEFs (a, b) as well as in isogenic p53+/+ MEFs (c, d). Fitness was
determined in four independent competition assays (24 hpi) at a 1:1 input ratio against a common competitor isogenic to the WT. Cytotoxicity was
calculated as the fraction of live cells at 18 hpi relative to uninfected cultures using the MTS assay. For each line, changes in viral fitness and
cytotoxicity were evaluated using a one-sample t-test against the WT value (*: P,0.05). The horizontal dashed lines indicate WT values, and error bars
indicate the SEM.
doi:10.1371/journal.pone.0102365.g001
Figure 2. Genetic changes found in the four evolved lines. For each gene, the nucleotide and amino acid substitutions are shown. Blue and
red squares indicate synonymous and non-synonymous substitutions, respectively. The C10224U substitution is in hatchet to indicate that this
position was polymorphic.
doi:10.1371/journal.pone.0102365.g002
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progression compared with either untreated mice (P,0.001) or
those treated with the WT virus (P= 0.002; Figure 5a). Interest-
ingly, strong differences in tumor growth were observed in the first
tumor measurements after each dose (days 2 and 9). Tumor
growth was minimal during the two days following the first dose of
L3 (1.3616.1 mm3/day) compared with untreated mice (58.769.1
mm3/day) or mice treated with the WT virus (59.7615.8 mm3/
day; Figure 5b). A similar pattern was reproduced during the two
days following the second dose (days 7–9), with the L3 virus
effectively controlling tumor growth in the short-term, as opposed
to the WT virus.
To test whether the increased oncolytic activity of L3 may also
be p53-dependent in vivo, we inoculated 24 mice with CT-26 cells
and, after 11 days, we applied the same treatment regime as above
to 10 mice for each virus type, with four mock-treated controls.
The experiment was terminated on day 7 post-treatment because
9/24 animals reached the endpoint criteria. Compared with
untreated controls, tumor growth was delayed in mice treated with
Figure 3. Western blot analysis of p53 expression and function. CT-26, Vero or 4T1 cells were irradiated with UV at the indicated doses to
induce DNA damage and tested 16 h post-irradiation for expression of p53, p21, and the constitutively expressed GAPDH. The Western blot shows
that p53 protein is expressed in all cells but is functional only in CT-26 and Vero cells, as judged by p21 levels.
doi:10.1371/journal.pone.0102365.g003
Figure 4. Half-maximal effective dose (EC50) of the evolved VSV lines L2 and L3, VSV WT and the VSV mutant MD51 in 4T1 and CT-
26 cells. Cells were inoculated at the indicated MOI and viability was measured after 48 h using the Alamar Blue assay. EC50 values and 95%
confidence intervals were inferred from non-linear least-squares regression of cell viability against the MOI, as detailed in the Methods section.
doi:10.1371/journal.pone.0102365.g004
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either the WT (one-way ANOVA: P= 0.004) or L3 viruses
(P= 0.041), but there were no differences between the L3 and WT
groups (P= 0.332; Figure 5c). Focusing on the first measurement
following viral inoculation, tumor growth was faster in the controls
(238632 mm3/day) than in mice treated with the WT (49.4628.9
mm3/day) or L3 (78.8622.9 mm3/day), but again there were no
differences between the two viruses (P= 0.436; Figure 5d).
Therefore, L3 did not show higher oncolytic activity than the
WT in CT-26 tumors.
Discussion
VSV provides a flexible platform for the design of oncolytic
viruses. Nearly all of the approximately 30 different oncolytic
VSVs reported in the literature have been produced by genetic
engineering, such as introduction of specific mutations in the M
and G proteins, generation of pseudotyped viruses expressing the
surface protein of other RNA viruses, insertion of microRNAs, or
insertion of genes encoding tumor suppressor (p53), suicide
(cytidine deaminase, timydine kinase) or immunomodularory (b-
interferon, interleukins) proteins [41]. In contrast, very few studies
have used evolutionary tools to try to increase the tumor selectivity
of VSV. In one such study, an engineered pseudotyped VSV
encoding a single-chain antibody against the Her2/neu receptor
(ErbB2) was found to yield low titer in target mammary cancer
cells expressing ErbB2, and directed evolution was then used to
improve viral fitness in these cells [14]. In another study, VSV was
serially passaged in human glioblastoma cells to select for more
efficient cell attachment, faster replication, and reduced affinity for
normal human fibroblasts [17]. The virus rapidly evolved the
desired properties and was later shown to be effective against other
tumor cell lines [18].
Here, we undertook a more general, experimental evolution
approach by serially passaging multiple independent evolution
lines in cells deficient for p53 function, a feature shared by many
cancers. Based on previous work showing extensive parallel
evolution in experimentally evolved VSV [23–26], we expected
that some substitutions should appear repeatedly after the 40 serial
passages. Parallel substitutions are excellent candidates to be
selectively advantageous, since it is unlikely that other evolutionary
forces such as random genetic drift can lead to the fixation of the
same mutations more than once. Therefore, use of multiple lines
should help us identify the molecular basis of the observed fitness
Figure 5. Effect of VSV L3 and WT on the growth of syngeneic Balb/c 4T1 and CT-26 tumors. Viruses were injected intratumorally 8 days
(4T1) and 11 days (CT-26) after engraftment, and a second dose was administered 7 days later to 4T1-bearing mice. The experiment was terminated
based on end-point criteria on days 14 (4T1) and 7 (CT-26). Top panels (a, c) show tumor growth throughout the course of the experiment for mice
treated with the VSV L3 (black circles), VSV WT (grey circles) and the mock-inoculated control group (white squares). Bottom panels (b, d) indicate the
tumor growth rate calculated between each viral dose and the first subsequent tumor measurement. The tumor growth rates of each group were
compared using t-tests (**: P,0.01; *: P,0.05; n.s.: P.0.05). Error bars indicate the SEM.
doi:10.1371/journal.pone.0102365.g005
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changes. However, we found that parallel evolution was weak in
our lines. The only repeated substitution (C10224U) was
polymorphic and was present in one line (L4) showing non-
specific adaptation to p532/2 cells. It is possible that, since p53
participates in the innate immune response against VSV [42],
p532/2 cells constitute a permissive environment for the virus,
thus allowing for the fixation of mutations that are effectively
neutral in p532/2 cells but deleterious in cells with normal p53
function by random genetic drift. Still, 3/4 lines showed
significantly increased fitness in p532/2 MEFs, indicating the
presence of positive selection.
VSV infection leads to secretion of type I interferons (IFNs),
which stimulate p53 transcription [42] and p53 post-translational
modifications including acetylation, phosphorylation, and SU-
MOylation [43,44], promoting apoptosis. As a result, p532/2
cells show partially defective apoptotic antiviral responses,
increasing the susceptibility of mice to VSV infection [42]. This
is further supported by the finding that a recombinant VSV
expressing p53 was highly attenuated in vivo [45]. In turn, the
ability of VSV to counteract the innate immune response is
mediated mainly by the matrix protein M, which shuts down
transcription, inhibits nuclear transport, and interferes with
cellular translation [46]. Therefore, mutations in some residues
of the M protein such as M51 that partially abolish these functions
are tolerated only in cells with crippled IFN pathways, including
many tumor cells [39,40]. Thus, p532/2 cells should offer a
permissive environment for the fixation of substitutions in the M
protein but, intriguingly, none of the four evolved lines showed
any mutation in this gene. The glycoprotein G also has also been
located in the nucleus or nuclear membrane [47], and substitu-
tions in several G residues such as E238 have been shown to
increase IFN secretion levels and selectivity for tumor cells [48],
thus echoing the properties of the M protein. In total, our evolved
lines contained three substitutions in the G protein, including
S273T in line L2, which maps to the end of the PH domain of the
protein in a non-structured region between two a-helices [49], but
L3 contained no changes in this gene. Finally, the leader and
trailer RNAs may also be implicated in the shutoff of cellular RNA
synthesis [50,51], but the presence of mutations in these regions
was not ascertained here.
Most oncolytic viruses including adenoviruses [52], herpex
simplex virus [53], and VSV [54] show limited efficacy against
4T1 syngeneic tumors. Treatment of metastatic 4T1 tumors with
the oncolytic VSV mutant M51R every two days during two weeks
did not achieve tumor regression and increased survival times only
modestly [54]. Not surprisingly, similarly modest results were
observed here. To date, significant improvement of VSV efficacy
against 4T1 tumors has been achieved only in combination with
other therapeutic agents, such as for instance by co-infecting
tumor cells with vaccinia virus [53,55] or using drugs such as
Sunitinib [56]. To this end, using a more active virus such as VSV
L3 may provide additional therapeutic benefit in combination
with these agents. Analogously to 4T1, it has been shown that
VSV MD51 has little effect on CT-26 tumors unless combined
with chemical sensitizers that inhibit the IFN response [57].
Interestingly, both the WT and L3 viruses retarded CT-26 tumor
growth rates significantly, albeit modestly, compared to untreated
controls, supporting the view that viruses in which attenuation is
not entirely dependent on the inability block IFN secretion are
good candidates to achieve efficient eradication of some IFN-
competent tumors. Since experimental evolution is an open-ended
process, it may help us identify these and other alternate
mechanisms of tumor-specific targeting.
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